Chempartner Pharmatech's P/S lags behind the industry due to falling revenue. Investors believe the potential for revenue improvement doesn't justify a higher P/S ratio. If recent revenue trends continue, significant share price movement seems unlikely.

Chempartner Pharmatech's shrinking revenues may cause a unstable P/S ratio, potentially disappointing shareholders. If recent medium-term revenue trends persist, significant share price movement seems unlikely.